4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads.

Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. 

Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.


Biotechnology

Health Care

Life Sciences

Therapeutics

4basebio

Heikki Lanckriet

Zoe Whiffen

Amy Walker

David Roth

The Quality Control team at 4basebio ensures the integrity, reliability, and safety of our synthetic DNA and mRNA products, as well as our Hermes™ non-viral delivery systems. Through rigorous testing and validation procedures, they maintain high standards of quality and compliance across all production processes, enabling the successful application of our technologies in next-generation cell and gene therapies, vaccines, and therapeutics.

Quality Control

Scientific Team

Quality Control

About

Team members

Other teams at 4basebio

Scientific Team